Molecular Pharmaceutics · 2009 · 23 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyMetastasisAntibody FunctionCancer ImmunotherapyImmunotherapy For Solid TumorsTargeted Cancer TherapyTumor Microenvironment ModulationTumor-associated AntigensAntibodiesExperimental Metastasis AssaysMonoclonal Antibodies In OncologyPhage Display ScreeningTargeted ImmunotherapyTumor Metastasis BiologyTumor-targeted Ligands
Despite significant progress and notable successes in tumor therapy, malignant disease remains an extremely difficult problem in today's health care setting. There is, however, an increasing application of new therapies targeting proteins specifically upregulated on tumor cells. These innovative therapeutic approaches are aimed at molecules that contribute to malignant development and progression but spare normal tissues. The CUB domain containing protein 1 (CDCP1) is such a tumor-associated protein and, thus, a potential candidate for targeted cancer immunotherapy. Herein, we describe the generation of function-blocking human antibodies against CDCP1 that were obtained from human scFv phage display libraries using subtractive panning protocols on CDCP1 expressing cancer cells and immunopurified CDCP1 protein. One of the isolated anti-CDCP1 antibodies, namely, C20Fc, efficiently blocked experimental metastasis of human carcinoma cells, including HeLa cells stably transfected with CDCP1 and prostate carcinoma cells PC-hi/diss naturally expressing CDCP1, in both chick embryo and mouse model systems. The C20Fc antibody also reduced colony formation of CDCP1 expressing cells in a soft agar assay for anchorage-independent cell growth. Specific targeting of CDCP1 by C20Fc mediated the delivery of a toxin-conjugated antibody complex, thus, providing evidence for antibody internalization and specific killing of CDCP1-positive tumor cells. Our findings indicate a functional role for CDCP1 in human cancer and underscore the therapeutic potential of function-blocking anti-CDCP1 antibodies targeting both primary and metastatic carcinoma cells.
27
The C2 Domain of PKCδ Is a Phosphotyrosine Binding Domain
Cyril H. Benes, Ning Wu, Andrew E. H. Elia et al. · Cell · 2005 · 255 citations · Full text
Transferrin receptor and its recycling in HeLa cells.
Jeffrey D. Bleil, Mark S. Bretscher · The EMBO Journal · 1982 · 206 citations · Full text
Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer
Marwa Scherl‐Mostageer, Wolfgang Sommergruber, Roger Abseher et al. · Oncogene · 2001 · 156 citations
Adhesion signaling by a novel mitotic substrate of src kinases
Ami S. Bhatt, Hediye Erdjument‐Bromage, Paul Tempst et al. · Oncogene · 2005 · 132 citations · Full text